Related Experiment Video
Updated: Sep 1, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Editorial: Immunotherapy in renal cell carcinoma
Viktor Gruenwald1, Walter J Storkus2
1Interdisciplinary Genitourinary Oncology, Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany.
This collection explores renal cell carcinoma (RCC) immunobiology and immunotherapy impacts. It highlights biomarkers for predicting patient outcomes and treatment response in RCC.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Renal cell carcinoma (RCC) is a significant oncological challenge.
- Understanding the tumor microenvironment and immune response is crucial for effective RCC treatment.
Discussion:
- The collection reviews advances in RCC immunobiology.
- It examines the efficacy and mechanisms of various immunotherapies for RCC.
- Biomarker identification for prognostication and predicting immunotherapy response is a key focus.
Key Insights:
- Specific immune cell populations and pathways are critical in RCC progression.
- Immunotherapy, including checkpoint inhibitors, shows significant promise in treating advanced RCC.
- Validated biomarkers can personalize treatment strategies and improve patient outcomes.
Outlook:
- Further research into novel immunotherapeutic targets and combination therapies is warranted.
- Continued biomarker discovery will refine patient stratification and treatment selection.
- Integrating immunobiological insights into clinical practice will enhance RCC management.
More Related Videos
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...